These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7767264)

  • 1. Preliminary analysis of clinical characteristics of patients enrolled in the HD01 protocol: a randomised trial of high dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's disease responding to first line therapy.
    Federico M; Clo V; Carella AM
    Leuk Lymphoma; 1995; 15 Suppl 1():63-6. PubMed ID: 7767264
    [No Abstract]   [Full Text] [Related]  

  • 2. High-dose therapy autologous stem cell transplantation vs conventional therapy for patients with advanced Hodgkin's disease responding to first-line therapy: analysis of clinical characteristics of 51 patients enrolled in the HD01 protocol. EBMT/ANZLG/Intergroup HD01 Trial.
    Federico M; Clò V; Carella AM
    Leukemia; 1996 Jun; 10 Suppl 2():s69-71. PubMed ID: 8649056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.
    André M; Henry-Amar M; Pico JL; Brice P; Blaise D; Kuentz M; Coiffier B; Colombat P; Cahn JY; Attal M; Fleury J; Milpied N; Nedellec G; Biron P; Tilly H; Jouet JP; Gisselbrecht C
    J Clin Oncol; 1999 Jan; 17(1):222-9. PubMed ID: 10458237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's lymphoma: a single center experience.
    Sperotto A; Zaja F; Damiani D; Patriarca F; Fanin R
    Haematologica; 2001 Dec; 86(12):1317-8. PubMed ID: 11726327
    [No Abstract]   [Full Text] [Related]  

  • 6. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
    Brice P; Bouabdallah R; Moreau P; Divine M; André M; Aoudjane M; Fleury J; Anglaret B; Baruchel A; Sensebe L; Colombat P
    Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy.
    Vigouroux S; Milpied N; Andrieu JM; Colonna P; Ifrah N; Colombat P; Desablens B; Abgrall JF; Casassus P; Guilhot F; Briere J; Le Mevel A; Moreau P; Mechinaud F; Mahe B; Morineau N; Vigier M; Rapp MJ; Harousseau JL
    Bone Marrow Transplant; 2002 May; 29(10):833-42. PubMed ID: 12058233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Sweetenham JW; Taghipour G; Milligan D; Blystad AK; Caballero D; Fassas A; Goldstone AH
    Bone Marrow Transplant; 1997 Nov; 20(9):745-52. PubMed ID: 9384476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.
    Federico M; Bellei M; Brice P; Brugiatelli M; Nagler A; Gisselbrecht C; Moretti L; Colombat P; Luminari S; Fabbiano F; Di Renzo N; Goldstone A; Carella AM;
    J Clin Oncol; 2003 Jun; 21(12):2320-5. PubMed ID: 12805333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
    Schmitz N; Pfistner B; Sextro M; Sieber M; Carella AM; Haenel M; Boissevain F; Zschaber R; Müller P; Kirchner H; Lohri A; Decker S; Koch B; Hasenclever D; Goldstone AH; Diehl V; ;
    Lancet; 2002 Jun; 359(9323):2065-71. PubMed ID: 12086759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
    Forrest DL; Hogge DE; Nevill TJ; Nantel SH; Barnett MJ; Shepherd JD; Sutherland HJ; Toze CL; Smith CA; Lavoie JC; Song KW; Voss NJ; Gascoyne RD; Connors JM
    J Clin Oncol; 2005 Nov; 23(31):7994-8002. PubMed ID: 16204014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous stem cell transplantation as adjuvant treatment vs no further therapy for poor-risk Hodgkin's disease in first complete remission after MOPP/ABVD.
    Carella AM; Pollicardo N; Pungolino E; Frassoni F; Giordano D; Bruni R; Spriano M; Rossi E
    Leuk Lymphoma; 1995; 15 Suppl 1():59-61. PubMed ID: 7539318
    [No Abstract]   [Full Text] [Related]  

  • 15. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
    Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical course and outcome of patients with Hodgkin's disease who progress after autologous transplantation.
    Varterasian M; Ratanatharathorn V; Uberti JP; Karanes C; Abella E; Momin F; Kasten-Sportes C; Al-Katib A; Lum L; Heilbrun LK
    Leuk Lymphoma; 1995 Dec; 20(1-2):59-65. PubMed ID: 8750624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
    Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
    Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.
    Lazarus HM; Rowlings PA; Zhang MJ; Vose JM; Armitage JO; Bierman PJ; Gajewski JL; Gale RP; Keating A; Klein JP; Miller CB; Phillips GL; Reece DE; Sobocinski KA; van Besien K; Horowitz MM
    J Clin Oncol; 1999 Feb; 17(2):534-45. PubMed ID: 10080597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of chemoresistance prior to autologous bone marrow transplantation for Hodgkin's disease.
    Voillat L; Deconinck E; Flesch M; Brion A; Rozenbaum A; Vuillier J; Pavy JJ; Angonin R; Carbillet JP; Hervé P
    Nouv Rev Fr Hematol (1978); 1994 Dec; 36(6):423-30. PubMed ID: 7753613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
    Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
    J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.